Fujifilm to Invest Over 200 Billion yen to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging

08-Jan-2021 - FUJIFILM Corporation is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO). FUJIFILM Diosynth ...

Fujifilm to invest 928 million USD to expand its large scale biologics production facility in Denmark

Doubling the drug substance production capacity

15-Jun-2020 - FUJIFILM Corporation will make a major capital investment of approximately 100billion yen(928 million USD)in the Denmark site of FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies. The capital investment ...

Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates

26-Oct-2012 - Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of ...

Diosynth Biotechnology appoints new president

30-Jan-2007 - Diosynth Biotechnology appointed Van Kimmenaede as new president. Van Kimmenaede, who joined Organon in 1986, served as general manager in the UK and in senior management roles in global marketing and manufacturing in Italy, the Netherlands and most recently in New Jersey, USA. On January 1, ...

Diosynth Biotechnology enters long-term commercial supply agreement with Dendreon

06-Mar-2006 - Diosynth Biotechnology announced that it has entered into a long-term commercial supply agreement with Dendreon Corporation for the manufacture of the recombinant antigen component of PROVENGE (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for prostate cancer. The ...

Vernalis signs agrrement with Diosynth Biotechnology for phase III manufacture of V10153

26-Sep-2005 - Vernalis Plc has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of V10153 for Phase III clinical trials. The process development and manufacturing agreement will see Vernalis transfer the manufacturing process developed by the company to the ...